Jenburkt Pharmaceuticals Limited has announced its financial results for the second quarter of fiscal year 2026, showcasing robust growth in both revenue and profitability.

Financial Highlights

The company reported a significant increase in its revenue from operations for the quarter ended September 30, 2025. Here's a breakdown of the key financial metrics:

The company's revenue from operations increased by 10.5% year-over-year, reaching Rs 4,555.70 lacs in Q2 FY2026 compared to Rs 4,121.50 lacs in the same quarter last year. This growth demonstrates the company's strong market position and effective business strategies.

Profit after tax also saw a notable rise, increasing by 11.3% to Rs 1,133.20 lacs from Rs 1,018.20 lacs in the corresponding period of the previous fiscal year. This improvement in profitability indicates efficient cost management and operational effectiveness.

Half-Year Performance

For the half-year period ended September 30, 2025, Jenburkt Pharmaceuticals reported total revenue of Rs 8,108.40 lacs, compared to Rs 7,375.16 lacs in the previous year, marking a 10% increase.

Segment Focus

Jenburkt Pharmaceuticals continues to operate exclusively in the pharmaceuticals business segment, maintaining its specialized focus in this industry.

Board Approval and Audit Review

The company's Board of Directors, on the recommendation of the Audit Committee, approved these unaudited financial results in a meeting held on October 28, 2025. The results have undergone a limited audit review by the company's auditors, D.R. Mehta & Associates, who found no material misstatements in the financial reporting.

Conclusion

Jenburkt Pharmaceuticals' Q2 FY2026 results reflect a period of solid growth and improved financial performance. The double-digit increase in both revenue and profit underscores the company's resilience and effective business strategies in the competitive pharmaceutical sector.

Jenburkt Pharmaceuticals , a prominent player in the pharmaceutical sector, has released its fourth-quarter financial results, showcasing robust growth across key metrics. The company has also announced a significant dividend payout for its shareholders.

Revenue Growth

For the fourth quarter, Jenburkt Pharmaceuticals reported a revenue of ₹410.50 crore, marking a notable increase from ₹388.00 crore in the same period last year. This 5.80% year-over-year growth demonstrates the company's ability to expand its market presence and drive sales despite challenging market conditions.

Improved Profitability

The company's profitability showed significant improvement in Q4:

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a substantial increase of 10.25%, rising to ₹108.60 crore from ₹98.50 crore in the previous year. This growth outpaced the revenue increase, indicating improved operational efficiency.

The EBITDA margin also showed significant expansion, reaching 26.45% compared to 24.37% in the same quarter last year. This 208 basis points improvement reflects the company's success in managing costs and enhancing profitability.

Net profit for the quarter stood at ₹85.40 crore, up from ₹79.00 crore in the previous year, representing a solid 8.10% increase. This growth in bottom-line performance underscores Jenburkt Pharmaceuticals' ability to translate higher revenues into increased profitability.

Dividend Announcement

In a move that will likely please shareholders, Jenburkt Pharmaceuticals has recommended a dividend of ₹18.00 per equity share. This dividend announcement reflects the company's strong financial position and its commitment to delivering value to its investors.

The robust financial performance and generous dividend payout demonstrate Jenburkt Pharmaceuticals' resilience and growth potential in the competitive pharmaceutical industry. Investors and market watchers will likely keep a close eye on the company's future performance and strategic initiatives as it continues to navigate the dynamic healthcare sector.